Dr. Cohen Discusses the KEYNOTE-040 Trial in Head and Neck Cancer

Name: Dr. Cohen Discusses the KEYNOTE-040 Trial in Head and Neck Cancer
Uploaded: 2017-09-22T21:00:00.000Z
Description: Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the phase III KEYNOTE-040 trial in head and neck cancer.

September 22, 2017

Ezra Cohen, MD

Video

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the phase III KEYNOTE-040 trial in head and neck cancer.

The KEYNOTE-040 trial evaluated pembrolizumab (Keytruda) versus standard of care in patients with recurrent or metatstaic head and neck squamous cell carcinoma.

This was the first effort in a randomized setting to demonstrate benefit, though statistically, it did not meet its endpoint.